Inceptionr LLC Invests $217,000 in LivaNova PLC (NASDAQ:LIVN)

Inceptionr LLC bought a new position in shares of LivaNova PLC (NASDAQ:LIVN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,696 shares of the company’s stock, valued at approximately $217,000.

Several other large investors also recently made changes to their positions in the business. Point72 Asset Management L.P. grew its holdings in shares of LivaNova by 62.7% during the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after purchasing an additional 806,374 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of LivaNova by 0.6% during the third quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock worth $70,676,000 after purchasing an additional 8,331 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of LivaNova by 16.6% during the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company’s stock worth $49,130,000 after purchasing an additional 133,401 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of LivaNova by 17.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock worth $32,678,000 after purchasing an additional 93,311 shares during the last quarter. Finally, Paradice Investment Management LLC grew its holdings in shares of LivaNova by 15.3% during the fourth quarter. Paradice Investment Management LLC now owns 486,821 shares of the company’s stock worth $22,545,000 after purchasing an additional 64,680 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now owns 7,522 shares of the company’s stock, valued at $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on LIVN shares. Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Stifel Nicolaus decreased their price target on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Needham & Company LLC decreased their price target on LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Mizuho decreased their price target on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group decreased their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, LivaNova presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.17.

LivaNova Trading Down 5.5 %

NASDAQ:LIVN opened at $37.02 on Tuesday. LivaNova PLC has a 1-year low of $36.85 and a 1-year high of $64.47. The business’s 50-day moving average price is $46.61 and its two-hundred day moving average price is $49.30. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of 88.14 and a beta of 1.10.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.